Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy

Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L, Baker R, Furrer H, Günthard HF, Freitas E, Humphreys I, Klenerman P, Mallal S, James I, Roberts S, Nolan D, Lucas M

(2009), Hepatology, 49(4), 1069-82

GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease

Berzsenyi M, Bowden DS, Roberts SK, Revill PA

(2009), J Gastroenterol Hepatol, 24(8), 1407-10

Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs

Sheffield LJ, Irving P, Gupta A, Byron K, Macrae FA, Phillimore H, Dronavalli M, Rose R, George P, Walmsley T, Dixon B, Poole S, Dooley M, Sparrow M

(2009), Pharmacogenomics, 10(7), 1091-9

Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C

Roberts SK, Cooksley G, Dore GJ, Robson R, Shaw D, Berns H, Hill G, Klumpp K, Najera I, Washington C

(2008), Hepatology, 48(2), 398-406

Urotensin II in chronic liver disease: in vivo effect on vascular tone.

Kemp W, Roberts S, Komesaroff PA, Zomer E, Krum H

(2008), Scand J Gastroenterol, 43(1), 103-9

Urotensin II in chronic liver disease: In vivo effect on vascular tone

Kemp W, Roberts S, Komesaroff PA, Zomer E, Krum H

(2007), Scand J Gastroenterol, 13, 1-7

Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis

Roberts S, Gordon A, McLean C, Pedersen J, Bowden S, Thomson K, Angus P

(2007), Clin Gastroenterol Hepatol, 5(8), 932-7

Hepatocellular carcinoma in an Australian tertiary referral hospital 1975-2002: change in epidemiology and clinical presentation

Roberts SK, Kemp W

(2007), J Gastroenterol Hepatol, 22(2), 191-6

Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection

Berzsenyi MD, Bowden DS, Kelly HA, Watson KM, Mijch AM, Hammond RA, Crowe SM, Roberts SK

(2007), Gastroenterology, 133(6), 1821-30

Therapeutic potential of blockade of the urotensin II system in systemic hypertension

Krum H, Kemp W

(2007), Curr Hypertens Rep, 9(1), 53-8

Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension

Kemp W, Krum H, Colman J, Bailey M, Yandle T, Richards M, Roberts S

(2007), Liver Int, 27(9), 1232-9

Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease

Kemp W, Pianko S, Nguyen S, Bailey MJ, Roberts SK

(2006), J Gastroenterol Hepatol, 21(8), 1355-6

Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C

Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, Roberts SK

(2006), J Gastroenterol Hepatol, 21(1 Pt 2), 275-80

Chronic hepatitis C virus infection: genotyping and its clinical role.

Bowden DS, Berzsenyi MD

(2006), Future Microbiol, 1, 103-12

What is the role of GB virus C infection in hepatitis C virus/HIV coinfection?

Berzsenyi MD, Roberts SK

(2006), J Infect Dis, 194(4), 407-9

Genomics of hepatitis B and C infections: diagnostic and therapeutic applications of microarray profiling

Berzsenyi MD, Roberts SK, Beard MR

(2006), Antivir Ther, 11(5), 541-52

26 27 28